MXPA00010241A - Composicion farmaceutica que comprende el factor viii y liposomas neutrales.. - Google Patents

Composicion farmaceutica que comprende el factor viii y liposomas neutrales..

Info

Publication number
MXPA00010241A
MXPA00010241A MXPA00010241A MXPA00010241A MXPA00010241A MX PA00010241 A MXPA00010241 A MX PA00010241A MX PA00010241 A MXPA00010241 A MX PA00010241A MX PA00010241 A MXPA00010241 A MX PA00010241A MX PA00010241 A MXPA00010241 A MX PA00010241A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
protein
factor viii
colloidal particles
polypeptide
Prior art date
Application number
MXPA00010241A
Other languages
English (en)
Spanish (es)
Inventor
Israel Nur
Original Assignee
Opperbas Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opperbas Holding Bv filed Critical Opperbas Holding Bv
Publication of MXPA00010241A publication Critical patent/MXPA00010241A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MXPA00010241A 1998-04-27 1999-04-23 Composicion farmaceutica que comprende el factor viii y liposomas neutrales.. MXPA00010241A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12422498 1998-04-27
PCT/IL1999/000217 WO1999055306A1 (en) 1998-04-27 1999-04-23 Pharmaceutical composition comprising factor viii and neutral liposomes

Publications (1)

Publication Number Publication Date
MXPA00010241A true MXPA00010241A (es) 2004-09-06

Family

ID=11071435

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA00010241A MXPA00010241A (es) 1998-04-27 1999-04-23 Composicion farmaceutica que comprende el factor viii y liposomas neutrales..

Country Status (12)

Country Link
US (2) US6593294B1 (cg-RX-API-DMAC10.html)
EP (1) EP1079805B1 (cg-RX-API-DMAC10.html)
JP (1) JP4545928B2 (cg-RX-API-DMAC10.html)
AT (1) ATE283034T1 (cg-RX-API-DMAC10.html)
AU (1) AU747391B2 (cg-RX-API-DMAC10.html)
BR (1) BR9909978A (cg-RX-API-DMAC10.html)
CA (1) CA2329768C (cg-RX-API-DMAC10.html)
DE (1) DE69922189T2 (cg-RX-API-DMAC10.html)
ES (1) ES2233036T3 (cg-RX-API-DMAC10.html)
MX (1) MXPA00010241A (cg-RX-API-DMAC10.html)
PT (1) PT1079805E (cg-RX-API-DMAC10.html)
WO (1) WO1999055306A1 (cg-RX-API-DMAC10.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110218B2 (en) 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
US20020132982A1 (en) * 2000-11-30 2002-09-19 Balasubramanian Sathyamangalam V. AHF associated dispersion system and method for preparation
US7625584B2 (en) * 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
DE60335469D1 (de) * 2002-07-02 2011-02-03 Univ Texas Radioaktiv markierte verbindungen und liposome und ihre herstellungs- und anwendungsverfahren
US7351688B2 (en) * 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
PT1633440E (pt) * 2003-04-15 2008-08-25 Opperbas Holding Bv Composição farmacêutica que compreende proteínas e/ou polipéptidos e partículas coloidais
WO2005017526A1 (en) * 2003-08-05 2005-02-24 The Research Foundation Of State University Of New York Reconstitution medium for protein and peptide formulations
US20070003607A1 (en) * 2003-09-02 2007-01-04 Vibhudutta Awasthi Neutral liposome-encapsulated compounds and methods of making and using thereof
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
PL1713446T3 (pl) * 2004-01-23 2011-05-31 Camurus Ab Nielamelarne trójskładnikowe kompozycje lipidów
DK2371856T3 (en) 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
US8895717B2 (en) * 2005-04-15 2014-11-25 The Board Of Regents Of The University Of Texas System Delivery of siRNA by neutral lipid compositions
BRPI0612843A2 (pt) * 2005-06-29 2010-11-30 The Research Foundation Of State University Of New York composição farmacêutica, métodos para fabricar a composição, e, uso de uma formulação
WO2007021822A2 (en) * 2005-08-09 2007-02-22 The Research Foundation Of State Of University Of New York At Buffalo Compositions and methods of preparation of liposomal microparticulate il-12
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
EP2007357B1 (en) * 2006-03-30 2016-11-09 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
DK2101821T3 (da) * 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
EP2299953B1 (en) 2008-07-14 2017-04-12 Polypid Ltd. Sustained-release drug carrier composition
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
CN102470105B (zh) 2009-07-14 2015-07-29 波利皮得有限公司 持续释放药物载体组合物
US10058837B2 (en) 2009-08-28 2018-08-28 The Trustees Of Columbia University In The City Of New York Systems, methods, and devices for production of gas-filled microbubbles
US20130028959A1 (en) 2009-12-16 2013-01-31 Massachusetts Institute Of Technology Liposomes for Preventing the Spread of HIV
EP2512588A4 (en) 2009-12-16 2014-06-04 Univ Columbia METHODS, DEVICES AND SYSTEMS FOR ULTRASOUND-RELEASED ON-DEMAND AGGREGATE FREEZING
JP5860409B2 (ja) 2010-01-19 2016-02-16 ポリピッド リミテッド 徐放性核酸マトリックス組成物
US8637448B2 (en) 2010-09-14 2014-01-28 University Of Rochester Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
DE102010043733A1 (de) 2010-11-10 2012-05-10 Oxprotect Gmbh Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
DK3164150T3 (da) 2014-07-02 2021-02-08 CSL Behring Lengnau AG Modificeret von willebrand-faktor
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
CA2986625A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
CA2986626A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
SG11201805494WA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
WO2017220099A1 (en) 2016-06-24 2017-12-28 Statens Serum Institut Adjuvants with modified drainage properties
WO2018005657A1 (en) 2016-06-28 2018-01-04 Verily Life Sciences Llc Serial filtration to generate small cholesterol-containing liposomes
DK3538133T3 (da) 2016-11-11 2021-04-19 CSL Behring Lengnau AG Trunkeret von willebrand faktor polypeptider til behandling af hæmofili
JP2020504082A (ja) 2016-11-11 2020-02-06 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド
GB202111757D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7900459A (nl) 1979-01-19 1980-07-22 Hendrik Coenraad Hemker Prof D Farmaceutisch preparaat en werkwijze ter bereiding daarvan.
JPS56127307A (en) * 1980-03-11 1981-10-06 Green Cross Corp:The Blood-coagulation factor 8 pharmaceutical for oral administration
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
WO1991012021A2 (en) * 1990-02-13 1991-08-22 Oxford Virology Plc Therapeutic agents, and intermediates for the synthesis thereof
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method

Also Published As

Publication number Publication date
EP1079805A1 (en) 2001-03-07
AU3441499A (en) 1999-11-16
CA2329768A1 (en) 1999-11-04
CA2329768C (en) 2008-06-10
ATE283034T1 (de) 2004-12-15
DE69922189D1 (de) 2004-12-30
US6930087B2 (en) 2005-08-16
BR9909978A (pt) 2000-12-26
AU747391B2 (en) 2002-05-16
JP2002512947A (ja) 2002-05-08
WO1999055306A1 (en) 1999-11-04
PT1079805E (pt) 2005-03-31
JP4545928B2 (ja) 2010-09-15
ES2233036T3 (es) 2005-06-01
US6593294B1 (en) 2003-07-15
DE69922189T2 (de) 2005-11-10
EP1079805B1 (en) 2004-11-24
US20030134778A1 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
PT1079805E (pt) Composicao farmaceutica compreendendo factor viii e lipossomas neutros
EP0783299A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
WO2002048183A3 (en) Compositions of peptide crystals
DE69312947D1 (de) Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe
DK0682524T3 (da) Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel
EP0993831A3 (en) Compounds and compositions for delivering active agents
EP2145897A3 (en) Therapeutic methods and compositions based on serrate proteins and nucleic acids
AU6819294A (en) Oral drug delivery compositions and methods
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
IS5087A (is) Stöðugar interferónlyfjablöndur á vökvaformi
AU2272097A (en) Drug delivery compositions suitable for intravenous injection
WO1997010851A3 (en) Nucleic acid delivery vehicle
ZA981478B (en) Use of interleukin-15
EP0997152A4 (en) MEDICINE AGAINST LYMPHATIC TUMORS
JP2002512947A5 (cg-RX-API-DMAC10.html)
EP0422125A4 (en) Platelet blocking peptides
AU2975899A (en) Colonic delivery of protein or peptide compositions
AU7683296A (en) Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them
WO2002058589A3 (en) Agents and methods for promoting bone growth
MXPA05010926A (es) Composicion farmaceutica que comprende proteinas y/o polipeptidos y particulas coloidales.
WO1994016723A3 (en) Wound healing composition
SG66504A1 (en) Pharmaceutical composition of hedgehog proteins and use thereof
WO2000071573A3 (en) Immunogenic peptides derived from mage and the use thereof
WO2003087329A3 (en) Targeted cytocidal virionoids for antiangiogenesis

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
PD Change of proprietorship

Owner name: CANTAB BIOPHARMACEUTICALS PATENTS LIMITED.*

PD Change of proprietorship

Owner name: CANTAB BIOPHARMACEUTICALS PATENTS LIMITED.*